肺鳞癌驱动基因及其靶向治疗的研究进展  

Progress in Lung Squamous Carcinoma Drive Gene and Its Targeted Therapy

作　　者：黄芳[1] 李颖[1] 姜达[1] 

机构地区：[1]河北医科大学第四医院,河北石家庄050035

出　　处：《肿瘤学杂志》2014年第12期1035-1039,共5页Journal of Chinese Oncology

摘　　要：应用分子靶向药物治疗晚期肺腺癌已逐渐成为当今临床研究的主流,其中EGFR基因突变患者可从靶向治疗中获益。肺鳞癌驱动基因的研究相对较少,近期多种检测技术对肺鳞癌标本进行基因检测,结果发现多数标本存在多个可测靶点,针对这些靶点已开发出一系列药物,其疗效仍待观察。Application of targeted therapy for advanced lung adenocarcinoma has gradually be- come the mainstream of the clinical research nowadays. Patients with EGFR mutation can bene- fit from it. Lung squamous carcinoma drive gene is relatively studied few. A variety of testing techniques for genetic testing lung squamous carcinoma specimens find that most of the speci- mens exist measurable targets. According to these targets it has developed a series of therapeu- tic drugs. However the effectiveness remains to be defined.

关 键 词：肺肿瘤 鳞状细胞 驱动基因 靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]